Product Reports Resources Pricing Login Book a demo

LumiraDx

Health Tech & Medtech · London, United Kingdom · Founded 2014 · Public via SPAC 2021

Delivers connected diagnostics and diagnostic-led care solutions

Valuation $382M
Revenue $10M

Talent graph

LumiraDx's talent

Book a demo to see the people
Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia 4 alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Where LumiraDx has talent and traffic

Workforce by country
30 countries with
team presence
🇬🇧 United Kingdom60.8%
🇺🇸 United States17%
🇩🇪 Germany4.1%
🇨🇴 Colombia3.9%
🇮🇹 Italy2.6%
Top 5 of 30 shown
Web traffic by country
130 monthly visits
across markets
🇺🇸 United States76.9%
Top 1 markets shown

Patent intelligence

$45M patent portfolio · 37 active families

Estimated portfolio value
$45M
11.7% of market cap · 5.5× smaller than top peer CMR Surgical ($243M)
37 active patent families
Where LumiraDx innovates ChemistryMolecular biologyAir liquid interfaceAnti immunoglobulinsAssay

Where LumiraDx concentrates vs peers

Each axis is a top-10 topic across LumiraDx and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Market sentiment

What the market is saying about LumiraDx

An AI-synthesized read of the highest-engagement posts about LumiraDx on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See LumiraDx on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.